Shots:

• Formycon and partner Bioeq have submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA
• Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases and other serious eye diseases. If approved- Coherus will commercialize FYB201 in the US
• Currently- Formycon has four biosimilars while Coherus also has a biosimilar bevacizumab CHS-305 which is currently under development in collaboration with Innovent

Ref: Formycon | Image: Formycon